Who Owns Gain Therapeutics Stock?
NASDAQ: GANXHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 19.82%
- Held by insiders
- 2.23%
- Institutional holders
- 55
- Institutions 19.8%
- Insiders 2.2%
- Public and other 77.9%
Who owns Gain Therapeutics stock?
Institutional investors own about 19.8% of Gain Therapeutics's shares, spread across 55 institutions that file 13F reports. That level of institutional ownership is relatively low, leaving more of the stock with retail investors and insiders. Insiders, including executives, directors and large founding shareholders, hold 2.23% of GANX.
The largest institutional holders are Marshall Wace LLP (4.41%), Potomac Capital Management, Inc. (2.17%) and GSA Capital Partners LLP (1.45%). Together, the top 10 institutions control 15.3% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their GANX positions and 2 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of GANX
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Marshall Wace LLP | 1.92M | 4.41% | +8.7% |
| Potomac Capital Management, Inc. | 946.40K | 2.17% | -6.2% |
| GSA Capital Partners LLP | 632.13K | 1.45% | +102.3% |
| Jones Financial Companies, L.L.L.P. | 608.59K | 1.39% | -3.6% |
| Cambridge Investment Research Advisors Inc. | 568.64K | 1.30% | 0.0% |
| DME Capital Management, LP | 566.13K | 1.30% | 0.0% |
| Vanguard Capital Management LLC | 480.27K | 1.10% | +20.1% |
| Geode Capital Management, LLC | 453.50K | 1.04% | +1.4% |
| Blackrock Inc. | 274.96K | 0.63% | +22.2% |
| Vanguard Fiduciary Trust Co | 231.53K | 0.53% | +0.7% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of GANX
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 430.90K | 0.99% |
| Fidelity Concord Street Trust-Fidelity Extended Market Index Fund | 221.61K | 0.51% |
| iShares Trust-iShares Micro-Cap ETF | 143.21K | 0.33% |
| Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund | 66.99K | 0.15% |
| Fidelity Concord Street Trust-Fidelity Total Market Index Fund | 57.34K | 0.13% |
| Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 23.51K | 0.05% |
| EQ Advisors Trust-1290 VT Micro Cap Portfolio | 9.73K | 0.02% |
| John Hancock Variable Insurance Trust-Total Stock Market Index Trust | 966 | 0.00% |
Frequently asked questions
Who is the largest shareholder of Gain Therapeutics?
Marshall Wace LLP is the largest institutional shareholder of GANX, owning 4.41% of shares outstanding (1.92M shares) as of its latest 13F filing.
What percentage of Gain Therapeutics is owned by institutions?
Institutions own about 19.8% of GANX shares and 20.3% of the public float.
How much of Gain Therapeutics do insiders own?
Insiders, such as officers and directors, own about 2.23% of GANX shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.